SRC-3: CoRegen’s revolutionary approach to cancer
Drug Target Review’s Taylor Mixides exclusively interviews David Lonard, PhD,…
Drug Target Review’s Taylor Mixides exclusively interviews David Lonard, PhD, Chief Scientific Officer at CoRegen and Associate Professor at Baylor University, to uncover the mechanisms of SRC-3 and why it’s key to targeting cancer – and only cancer.